Edesa Biotech Future Growth
Future criteria checks 0/6
Edesa Biotech's earnings are forecast to decline at 39.5% per annum. EPS is expected to grow by 12.4% per annum.
Key information
-39.5%
Earnings growth rate
12.4%
EPS growth rate
| Biotechs earnings growth | 27.6% |
| Revenue growth rate | n/a |
| Future return on equity | n/a |
| Analyst coverage | Low |
| Last updated | 20 Aug 2024 |
Recent future growth updates
Recent updates
Edesa Biotech (NASDAQ:EDSA) Will Have To Spend Its Cash Wisely
Aug 04
We're Keeping An Eye On Edesa Biotech's (NASDAQ:EDSA) Cash Burn Rate
Mar 10Edesa shares jump ~11%, says monoclonal antibody cuts risk of death due to COVID by 84%
Sep 30Edesa Biotech (NASDAQ:EDSA) Is In A Good Position To Deliver On Growth Plans
Sep 23Edesa says mid-stage trial for anti-allergic cream reached full enrollment
Sep 07Edesa Biotech GAAP EPS of -$0.37 beats by $0.06
Aug 12Companies Like Edesa Biotech (NASDAQ:EDSA) Can Afford To Invest In Growth
May 16Edesa Biotech: Leader In Developing Treatments For COVID-19 And ACD
Apr 18Here's Why We're A Bit Worried About Edesa Biotech's (NASDAQ:EDSA) Cash Burn Situation
Dec 08Edesa Biotech Reports Positive Phase 2 Data In Critically-Severe COVID Patients
Sep 22Here's Why We're A Bit Worried About Edesa Biotech's (NASDAQ:EDSA) Cash Burn Situation
Aug 27Edesa Biotech soars 10% on favorable DSMB review of COVID-19 study
Jun 18Is Edesa Biotech (NASDAQ:EDSA) In A Good Position To Deliver On Growth Plans?
Apr 13Director Frank Oakes Just Sold A Bunch Of Shares In Edesa Biotech, Inc. (NASDAQ:EDSA)
Feb 19Edesa Biotech receives C$14M for COVID-19 study
Feb 02Edesa Biotech (NASDAQ:EDSA) Is In A Good Position To Deliver On Growth Plans
Dec 08
Edesa Biotech EPS misses by $0.04, beats on revenue
Dec 07Edesa Biotech's lead asset mid-stage dermatitis study achieves 50% enrollment
Nov 03Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 9/30/2026 | N/A | -14 | N/A | N/A | 1 |
| 9/30/2025 | N/A | -11 | N/A | N/A | 2 |
| 9/30/2024 | N/A | -6 | -5 | -5 | N/A |
| 6/30/2024 | N/A | -7 | -5 | -5 | N/A |
| 3/31/2024 | N/A | -7 | -6 | -6 | N/A |
| 12/31/2023 | N/A | -8 | -6 | -6 | N/A |
| 9/30/2023 | N/A | -8 | -7 | -7 | N/A |
| 6/30/2023 | N/A | -9 | -11 | -11 | N/A |
| 3/31/2023 | N/A | -13 | -12 | -12 | N/A |
| 12/31/2022 | N/A | -16 | -11 | -11 | N/A |
| 9/30/2022 | N/A | -18 | -12 | -12 | N/A |
| 6/30/2022 | N/A | -18 | -7 | -7 | N/A |
| 3/31/2022 | N/A | -17 | -7 | -7 | N/A |
| 12/31/2021 | N/A | -15 | -14 | -14 | N/A |
| 9/30/2021 | N/A | -13 | -14 | -14 | N/A |
| 6/30/2021 | 0 | -12 | -15 | -15 | N/A |
| 3/31/2021 | 0 | -9 | -13 | -13 | N/A |
| 12/31/2020 | 0 | -8 | -7 | -7 | N/A |
| 9/30/2020 | 0 | -6 | -5 | -5 | N/A |
| 6/30/2020 | 1 | -5 | -5 | -5 | N/A |
| 3/31/2020 | 1 | -5 | -6 | -6 | N/A |
| 12/31/2019 | 1 | -4 | -6 | -6 | N/A |
| 9/30/2019 | 0 | -3 | -5 | -5 | N/A |
| 6/30/2019 | 0 | -3 | -4 | -4 | N/A |
| 3/31/2019 | N/A | -2 | -1 | -1 | N/A |
| 12/31/2018 | N/A | -2 | -1 | -1 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: EDSA is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: EDSA is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: EDSA is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: Insufficient data to determine if EDSA's revenue is forecast to grow faster than the US market.
High Growth Revenue: EDSA is forecast to have no revenue next year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if EDSA's Return on Equity is forecast to be high in 3 years time
Discover growth companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/27 15:53 |
| End of Day Share Price | 2024/12/27 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2024/09/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Edesa Biotech, Inc. is covered by 2 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Vernon Bernardino | H.C. Wainwright & Co. |
| David Bautz | Zacks Small-Cap Research |